Real World Outcomes of Treating CLL with Liso-Cel
March 5, 2026
In the real-world, patients with CLL treated with liso-cel have response rates that are just as good or even higher than those seen in clinical trials.
In the real-world, patients with CLL treated with liso-cel have response rates that are just as good or even higher than those seen in clinical trials.
February 2026 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Dr. Meghan C. Thompson and Michele Nadeem-Baker joins us for CLL Society’s Facebook Live Event “Ask Me Anything”
The presence of certain precancerous mutations may predispose patients to increased risk of developing certain side effects in response to therapies.
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
CLL Society awarded Dr. Matthews Davids a research grant for his project Optimizing Glofitamab Combination Therapy in Richter’s Transformation.
Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.
The time-limited combination of duvelisib plus venetoclax was effective for treating relapsed / refractory CLL, but it also had significant side effects.
Hodgkin lymphoma transformation is a rare type of Richter’s transformation in which CLL / SLL turns into Hodgkin lymphoma rather than DLBCL.